Physician profile
John Cheng
NPI 1619061397
$495.44
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $131 · 2020: $235 · 2021: $51.79 · 2022: $78.10.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $93.11 | 2019-2020 | |
| Glaxosmithkline, LLC. | $69.77 | 2019-2022 | |
| Antares Pharma, INC. | $63.19 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $51.64 | 2019-2020 | |
| Allergan, INC. | $39.12 | 2020 | |
| Merck Sharp & Dohme LLC | $38.02 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $37.84 | 2022 | |
| Dermira, INC. | $22.85 | 2020 | |
| Jazz Pharmaceuticals INC. | $17.80 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $17.44 | 2021 | |
| Sanofi Pasteur INC. | $16.21 | 2019 | |
| Bausch Health US, LLC | $14.30 | 2020 | |
| Abbvie INC. | $14.15 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Cheng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.